secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2022-04-21T23:59:59+00:00
Accession:  0001193125-22-113203
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology appoints Albert Seymour President; Tzianabos remains CEO, Seymour gets new equity grant
--------------------------------------------------------------------------------

- Albert Seymour promoted to President effective April 21, 2022, while remaining Chief Scientific Officer.
- Arthur Tzianabos resigns as President but continues as Chief Executive Officer of Homology.
- Seymour's base salary increased to $545,000; target annual bonus set at 50% of base salary.
- Seymour receives option to purchase 60,000 shares at $1.78, vesting over 48 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522113203/0001193125-22-113203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522113203/d304763d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-113203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer